Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)
Needham Maintains Lexicon Pharmaceuticals(LXRX.US) With Hold Rating
Lexicon Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $4
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $1.2
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $4
Needham Maintains Lexicon Pharmaceuticals(LXRX.US) With Hold Rating
Lexicon Pharmaceuticals Analyst Ratings
HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating
Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
Lexicon Pharmaceuticals (LXRX) Gets a Buy From Piper Sandler
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
Needham Maintains Lexicon Pharmaceuticals(LXRX.US) With Hold Rating
Lexicon Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI) and Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
Lexicon Pharma Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $6